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Study of Heart and Renal Protection (SHARP):
Randomized trial to assess the effects of lowering
low-density lipoprotein cholesterol among 9,438
patients with chronic kidney disease
SHARP Collaborative Group
Background Lowering low-density lipoprotein (LDL) cholesterol with statin therapy has been shown to reduce the
incidence of atherosclerotic events in many types of patient, but it remains uncertain whether it is of net benefit among people
with chronic kidney disease (CKD).
Methods Patients with advancedCKD (blood creatinine ≥1.7mg/dL [≥ 150 μmol/L] in men or ≥1.5mg/dL [ ≥ 130 μmol/L]
in women) with no known history of myocardial infarction or coronary revascularization were randomized in a ratio of 4:4:1 to
ezetimibe 10 mg plus simvastatin 20 mg daily versus matching placebo versus simvastatin 20 mg daily (with the latter arm
rerandomized at 1 year to ezetimibe 10 mg plus simvastatin 20 mg daily vs placebo). The key outcome will be major
atherosclerotic events, defined as the combination of myocardial infarction, coronary death, ischemic stroke, or any
revascularization procedure.
Results A total of 9,438 CKD patients were randomized, of whom 3,056 were on dialysis. Mean age was 61 years, two
thirds were male, one fifth had diabetes mellitus, and one sixth had vascular disease. Compared with either placebo or
simvastatin alone, allocation to ezetimibe plus simvastatin was not associated with any excess of myopathy, hepatic toxicity,
or biliary complications during the first year of follow-up. Compared with placebo, allocation to ezetimibe 10 mg plus
simvastatin 20 mg daily yielded average LDL cholesterol differences of 43 mg/dL (1.10 mmol/L) at 1 year and 33 mg/dL
(0.85 mmol/L) at 2.5 years. Follow-up is scheduled to continue until August 2010, when all patients will have been followed
for at least 4 years.
Conclusions SHARP should provide evidence about the efficacy and safety of lowering LDL cholesterol with the
combination of ezetimibe and simvastatin among a wide range of patients with CKD. (Am Heart J 2010;160:785-794.e10.)
Background
Observational studies in unselected populations have
shown that there is a continuous positive relationship
between coronary heart disease (CHD) risk and blood
low-density lipoprotein (LDL) cholesterol that extends
well below the range seen in Western populations.1,2 A
meta-analysis of randomized trials has shown that statin
therapy reduces the incidence of major coronary events
(nonfatal myocardial infarction [MI] or CHDmortality), of
ischemic strokes, and of coronary revascularizations by
about one fifth for every 1-mmol/L (39-mg/dL) reduction
in LDL cholesterol, while producing no benefit on
hemorrhagic stroke or on vascular causes of death
other than CHD.3,4 Among people without known
chronic kidney disease (CKD), in whom estimated
glomerular filtration rate (eGFR) is typically greater than
about 60 mL/min/1.73 m2, the proportional reduction in
the risk of a major vascular event (ie, major coronary
event, stroke, or coronary revascularization) appears to
be independent of renal function.4
The etiology of cardiovascular disease among patients
with preserved renal function (or only minor renal
dysfunction) is typically atherosclerotic, but a quite
distinct type of cardiovascular pathology is observed
once GFR falls to less than about 30 mL/min/1.73 m2.
Several mechanisms resulting from renal metabolic
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Trial Design
dysregulation (eg, arterial calcification, left ventricular
hypertrophy, and sympathetic overactivity) are believed
to contribute to an increased risk of cardiac arrhythmia
and heart failure.5 A key question, therefore, is whether
reducing LDL cholesterol can prevent the types of
vascular events (notably sudden cardiac death) that
predominate as renal impairment progresses. Two
randomized trials have examined the effects of lowering
LDL cholesterol with statin therapy among dialysis
patients. In the 4D randomized trial of atorvastatin
20 mg daily versus placebo among 1,255 hemodialysis
patients with type 2 diabetes, lowering LDL cholesterol
by an average of 39 mg/dL (1.0 mmol/L) for a median of
4 years yielded a nonsignificant 8% reduction in the
prespecified primary outcome of cardiac death, nonfatal
MI, or stroke.6 Similarly, in the AURORA randomized trial
of rosuvastatin 10 mg daily versus placebo among 2,776
hemodialysis patients, lowering LDL cholesterol by an
average of 39 mg/dL (1.0 mmol/L) for 4 years yielded a
nonsignificant 4% reduction in the primary outcome of
cardiovascular death, nonfatal MI, or stroke.7 A high
proportion of cardiac deaths in these trials was not
attributable to CHD, and there was no evidence in either
trial of a reduction in the risk of such deaths.6,7 However,
although lowering LDL cholesterol with statin therapy
among patients with end-stage renal failure did not
produce statistically significant reductions in the primary
outcomes in these trials, there were promising propor-
tional reductions of 18% (relative risk 0.82, 95% CI 0.68-
0.99, P = .03) in major cardiac events in the 4D trial6 and
of 16% (relative risk 0.84, 95% CI 0.64-1.11, P = .2) in
nonfatal MI in the AURORA trial.7 These findings raise the
possibility of small, but worthwhile, proportional benefits
on atherosclerotic outcomes among dialysis patients and
of larger proportional benefits among those with less
severe renal impairment (in whom a higher proportion of
events is likely to be atherosclerotic).
The Study of Heart and Renal Protection (SHARP) aims
to address these uncertainties by assessing the effects
of reducing LDL cholesterol by an average of about
1 mmol/L among about 9,000 patients with CKD (about
3,000 of whom were to be on dialysis at randomization).
The first United Kingdom–Heart and Renal Protection
(UK-HARP-1) pilot study8 indicated that, to obtain an
average absolute reduction in LDL cholesterol of
1 mmol/L in a large-scale trial lasting 4 to 5 years, it
was likely to be necessary to use a regimen that could
reduce LDL cholesterol by about 45% to 50%. To
achieve such a reduction without the use of high statin
doses (which are associated with an increased risk of
myopathy,9 especially in patients with impaired renal
function10), a low dose of a statin (simvastatin 20 mg
daily) was combined with the cholesterol-absorption
inhibitor ezetimibe, and the biochemical efficacy and
tolerability of this regimen were confirmed in the
UK-HARP-II pilot study.11
Inclusion and exclusion criteria
Inclusion criteria
• History of CKD
○ Predialysis (blood creatinine ≥1.7 mg/dL [≥150
μmol/L] in men or ≥1.5 mg/dL [≥130 μmol/L] in
women at both the most recent routine clinic
visit and the study screening visit) or
○ Dialysis (hemodialysis or peritoneal dialysis)
• Men or women aged ≥40 years
Exclusion criteria
• Definite history of MI or coronary revascularization
procedure
• Functioning renal transplant or living donor renal
transplant planned
• Less than 2 months since presentation as an acute
uremic emergency
• Definite history of chronic liver disease or
abnormal liver function (ie, ALT N1.5× ULN or, if
ALT not available, AST N1.5× ULN) (patients with a
history of hepatitis are eligible if these limits are
not exceeded)
• Evidence of active inflammatory muscle disease
(eg, dermatomyositis, polymyositis) or CK N3× ULN
• Definite previous adverse reaction to a statin or to
ezetimibe
• Concurrent treatment with a contraindicated drug:
○ Hydroxymethylglutaryl–coenzyme A reductase
inhibitor (“statin”)
○ Ezetimibe
○ Fibric acid derivative (“fibrate”)
○ Nicotinic acid
○ Ciclosporin
○ Macrolide antibiotic (erythromycin, clarithromycin)
○ Systemic use of imidazole or triazole antifungals
(eg, itraconazole, ketoconazole)
○ Protease-inhibitors (eg, antiretroviral drugs for
HIV infection)
○ Nefazodone
• Child-bearing potential (ie, premenopausal woman
who is not using a reliable method of contraception)
• Known to be poorly compliant with clinic visits or
prescribed medication
• Medical history that might limit the individual's
ability to take the trial treatments for the duration
of the study (eg, severe respiratory disease, history
of cancer other than nonmelanoma skin cancer, or
recent history of alcohol or substance misuse)
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Although the chief aim of SHARP is to determine any
vascular benefits of LDL lowering among patients with
advanced CKD, the trial also provides an opportunity to
test the hypothesis that lowering LDL cholesterol might
reduce the rate of loss of renal function.12 Among people
without known CKD, meta-analyses of randomized trials
have suggested that statin therapy might reduce the rate
of loss of eGFR by about one third13,14; so a similar
proportional effect among patients with advanced CKD,
in whom there is rapid loss of renal function, would yield
a worthwhile delay in the need for renal replacement
therapy (ie, dialysis or transplantation).
In this article, we describe the SHARP trial design,
patient characteristics, early safety data, lipid effects, and
statistical analysis plan.
Methods
Aims
SHARP aims to assess the efficacy and safety of lowering
LDL cholesterol with the combination of ezetimibe 10 mg
plus simvastatin 20 mg (ezetimibe/simvastatin 10/20 mg)
daily among men or women aged at least 40 years without
known CHD (prior MI or coronary revascularization) who
had evidence of CKD (determined by screening creatinine
≥1.7 mg/dL [≥150 μmol/L] in men or ≥1.5 mg/dL
[≥130 μmol/L] in women; Box). It was intended to recruit
about 3,000 CKD patients requiring dialysis and 6,000 not on
dialysis. Using a “double-dummy” method to maintain
blinding for both patients and physicians, patients were
randomized in a ratio of 4:4:1 to ezetimibe/simvastatin 10/
20 mg daily versus matching placebo versus simvastatin 20
mg daily (Figure 1). After 1 year, patients initially allocated
simvastatin 20 mg daily alone (who formed a comparison
group for the assessment of any early adverse effects of
ezetimibe) were rerandomized to ezetimibe/simvastatin 10/20
mg daily versus placebo for the remainder of the scheduled
study treatment period.
Sample size and predicted number of events
A meta-analysis of statin trials available in 2000 (which was
subsequently published3) indicated that statin therapy produced
a reduction of about one quarter in major vascular events
(defined as cardiac death, nonfatal MI, coronary revasculariza-
tion, or stroke) per 1-mmol/L LDL cholesterol reduction. Based
on the expectation that ezetimibe/simvastatin 10/20 mg would
reduce LDL cholesterol by an average of 39 mg/dL (1 mmol/L) in
the SHARP trial, together with the assumption that about one
fifth of cardiac deaths might be nonatherosclerotic (and, hence,
potentially not susceptible to prevention by lowering LDL
cholesterol), it was hypothesized that the risk of major vascular
events might be reduced by 20%. The annual incidence of major
vascular events was projected to be about 5% among CKD
patients on dialysis at baseline and about 3% among those who
were not, so the average event rate during follow-up was
estimated to be 3.7% per annum (based on 1:2 ratio of these
groups). Under these assumptions, a study in which all patients
were followed for at least 4 years from trial entry, yielding at
least 1,100 major vascular events, would have 90% power at P b
.01 (2-sided).
Based on the UK-HARP-I pilot study8 and the RENAAL
study,15 the cumulative incidence of end-stage renal disease
(defined as starting long-term dialysis or transplantation)
among patients not on dialysis at baseline was expected to
be about 20% after 4 years. Consequently, the inclusion of
6,000 such patients in SHARP provides N95% power at P b .01
(2-sided) to detect a 20% relative reduction in the risk of end-
stage renal disease.
Figure 1
SHARP randomization structure.
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Results
Screening clinic visit
SHARP has been conducted in 380 hospitals in 18
countries. Between June 2003 and June 2006, 11,792
potentially eligible CKD patients attended the study
screening visits. Medical history and other eligibility
criteria were checked (Box), and 11,364 (96%) eligible
patients agreed to participate. Among these patients,
written informed consent was obtained; blood pressure,
height, weight, and waist circumference were mea-
sured; nonfasting blood was taken for local laboratory
assays (lipid profile, creatine kinase [CK], alanine
aminotransferase [ALT] or aspartate aminotransferase
[AST], creatinine); and single-blind study placebo tablets
were provided. Study data were entered directly into
electronic case-report forms on dedicated laptop
computers.
Run-in period before randomization
During run-in, the patient's physicians were provided
with a summary of the screening data for each of their
patients, including the results of local laboratory blood
assays on screening blood samples. Randomization
could be considered at the end of the run-in period
only if the responsible physician (typically the nephrol-
ogist) confirmed that this was appropriate and no
objection had been raised by any other physician caring
for the patient. Patients who were noncompliant (ie,
took b90% of run-in treatment) or who were thought
likely to have difficulties in attending clinics for any
reason were not to be randomized. Hence, in addition to
allowing a review by the patient's physicians, the run-in
period allowed many potential dropouts to be excluded
before being randomized, with a consequent improve-
ment in statistical sensitivity.16
Table I. Baseline demographic characteristics, overall and by renal status at randomization
Not on dialysis On dialysis All patients
Number randomized 6382 3056 9438
Renal diagnosis
Glomerulonephritis 1063 (17%) 689 (23%) 1752 (19%)
Diabetic nephropathy 916 (15%) 477 (16%) 1393 (15%)
Hypertensive or renovascular disease 1334 (22%) 482 (16%) 1816 (20%)
Cystic kidney disease 690 (11%) 374 (12%) 1064 (12%)
Pyelonephritis/obstructive nephropathy 413 (7%) 202 (7%) 615 (7%)
Other known cause 911 (15%) 373 (12%) 1284 (14%)
Unknown cause 796 (13%) 403 (13%) 1199 (13%)
Unavailable 259 56 315
Age, y
Mean (SD) 62.3 (11.7) 58.9 (11.8) 61.2 (11.9)
40-49 1099 (17%) 825 (27%) 1924 (20%)
50-59 1516 (24%) 826 (27%) 2342 (25%)
60-69 1794 (28%) 740 (24%) 2534 (27%)
70+ 1973 (31%) 665 (22%) 2638 (28%)
Sex
Men 3954 (62%) 1946 (64%) 5900 (63%)
Women 2428 (38%) 1110 (36%) 3538 (37%)
Physical measurements
Systolic blood pressure, mm Hg 139 (21) 139 (24) 139 (22)
Diastolic blood pressure, mm Hg 80 (13) 78 (13) 79 (13)
Body mass index, kg/m2 27.4 (5.5) 26.4 (5.8) 27.1 (5.6)
Waist circumference, cm 96.7 (14.8) 97.0 (15.7) 96.8 (15.1)
Smoking
Current smoker 791 (12%) 475 (16%) 1266 (13%)
Prior diseases⁎
Angina 212 (3%) 77 (3%) 289 (3%)
Peripheral arterial disease 371 (6%) 229 (7%) 600 (6%)
Cerebrovascular disease 464 (7%) 187 (6%) 651 (7%)
Any vascular disease 933 (15%) 437 (14%) 1370 (15%)
Diabetes 1429 (22%) 650 (21%) 2079 (22%)
Ethnic group
White 4567 (72%) 2206 (72%) 6773 (72%)
Black 130 (2%) 146 (5%) 276 (3%)
Chinese 1031 (16%) 109 (4%) 1140 (12%)
Other Asian 528 (8%) 442 (14%) 970 (10%)
Other/not specified 126 (2%) 153 (5%) 279 (3%)
Mean (SD) or number (percentage) shown.
⁎Cerebrovascular disease includes stroke and transient ischemic attack. Any vascular disease is defined as a history of angina, peripheral arterial disease, or cerebrovascular
disease at the screening visit.
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Randomization clinic visit
Participating patients returned for a randomization
appointment approximately 6 weeks after the screening
visit. Those who had not had a serious adverse event
rendering them ineligible during the run-in period (eg,
MI) and who had not commenced a contraindicated drug
(eg, statin) were asked if they were still willing to take
study treatment for at least 4 years. A total of 1,926
patients entered run-in but were not randomized. Of
these, 1,678 dropped out before the randomization visit,
with the reasons given including (N1 reason was possible)
the following: patient's request (23%), physician's request
(44%), ineligible screening blood result (32%), or some
other reason (11%). A further 248 patients attended the
randomization visit but were not randomized, generally
because of poor compliance during run-in or their
reluctance to continue. Patients who agreed to be
randomized provided nonfasting blood samples and, if
not on dialysis, a urine sample, and were asked for their
consent for long-term storage of plasma, DNA, and urine
for unspecified future analyses. Samples were cooled,
spun, and separated locally, whereupon plasma and
whole blood aliquots were stored locally at −40°C before
shipment on dry ice to the central laboratory (Wolfson
Laboratories, CTSU, University of Oxford, United King-
dom). Patients were allocated their study treatment using
a minimized randomization algorithm on the laptop
computer (which was synchronized regularly with the
central database) to help ensure balance with respect to
important prognostic characteristics.17
A total of 9,438 CKD patients were randomized, of
whom 3,056 were receiving maintenance dialysis (2,556
hemodialysis and 500 peritoneal dialysis) and 6,382 were
not (Table I). The most common recorded causes of renal
disease were glomerulonephritis (19%), diabetic ne-
phropathy (15%), and hypertensive or renovascular
disease (20%). Mean age was 61 years (SD 12), 63%
were male, mean blood pressure was 139/79 mm Hg,
mean body mass index was 27.1 (SD 5.6) kg/m2, and 22%
had diabetes. Patients who had a prior history of MI or
coronary revascularization were not eligible, but 15% had
some other vascular disease (eg, angina pectoris, stroke,
or peripheral vascular disease). About three quarters of
the study population were white, whereas 3%were black,
12% were Chinese, and 10% were other Asian.
Among the 6,382 patients not on dialysis at randomi-
zation, the average eGFR, calculated with the Modified
Diet and Renal Disease equation18, was 26.5 (SD 13.0)
mL/min/1.73 m2 (Table II). About two fifths of the
patients not on dialysis had Kidney Disease Outcomes
Quality Initiative19 stage 3 disease (eGFR of 30-59 mL/
min/1.73 m2), two fifths had stage 4 disease (eGFR of
15-29 mL/min/1.73 m2), and one fifth had stage 5 disease
(eGFR b15 mL/min/1.73 m2). Among the 5,681 (89%)
nondialysis patients who had a measurement of urinary
albumin to creatinine ratio (ACR), about one fifth had
values in the reference range (ACR b30 mg/g), two fifths
had microalbuminuria (ACR ≥30 and ≤300 mg/g), and
two fifths had macroalbuminuria (ACR N300 mg/g).
Overall, among the 9,044 patients for whom a blood
sample was available at randomization, mean plasma
concentrations were 189 (SD 45) mg/dL for total
cholesterol, 108 (SD 34) mg/dL for LDL cholesterol,
43 (SD 13) mg/dL for high-density lipoprotein (HDL)
cholesterol, and 206 (SD 152, interquartile range 119-249)
mg/dL for triglycerides. Mean LDL cholesterol concen-
tration was lower among patients on dialysis than those
who were not (100 vs 111 mg/dL, P b .0001).
Aspirin or other antiplatelet therapy was being pre-
scribed at baseline to 22% of randomized patients and an
oral anticoagulant to 4% (Table III). As expected in this
high-risk CKD population, a high proportion were
receiving angiotensin-converting-enzyme (ACE) inhibi-
tors (35% of all patients), angiotensin-receptor blockers
(23%), calcium-channel blockers (41%), β-blockers (37%),
and diuretics (42%), with many (60%) receiving N1 of
these agents.
Postrandomization follow-up visits
Participants were to be seen in the study clinics for
routine follow-up at 2 months, at 6 months, and then
Table II. Laboratory values at randomization, overall and by
renal status at randomization
Not on
dialysis
On
dialysis
All
patients
Number randomized 6382 3056 9438
eGFR, mL/min/1.73 m2
Mean (SD) 26.5 (13.0) – –
b15 1237 (20%) – –
15-29 2628 (43%) – –
30-59 2197 (36%) – –
60-89 67 (1%) – –
≥ 90 21 (0%) – –
Missing 232
Urinary ACR
Normal 1124 (20%) – –
Microalbuminuria 2125 (37%) – –
Macroalbuminuria 2432 (43%) – –
Missing 701
Lipids
Number with baseline
LDL cholesterol analyzed
6149 (96%) 2895 (95%) 9044 (96%)
Total cholesterol, mg/dL 194 (45) 179 (45) 189 (45)
LDL cholesterol, mg/dL 111 (33) 100 (33) 108 (34)
HDL cholesterol, mg/dL 44 (13) 42 (13) 43 (13)
Triglycerides, mg/dL 206 (146) 206 (164) 206 (152)
Apolipoprotein B, mg/dL 99 (25) 92 (26) 96 (26)
Apolipoprotein A1, mg/dL 136 (29) 129 (27) 134 (29)
Apolipoprotein B:
apolipoprotein A1
0.75 (0.23) 0.74 (0.24) 0.75 (0.24)
Mean (SD) or number (percentage) shown. Microalbuminuria is defined as an ACR
≥30 and ≤300 mg/g. Macroalbuminuria is defined as ACR >300 mg/g. To convert
milligrams per deciliter to millimoles per liter, multiply by 0.02586 for cholesterol and
by 0.01129 for triglycerides; to convert apolipoprotein A1 and B from milligrams per
deciliter to grams per liter, divide by 100.
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every 6 months until the final follow-up visits between
March and August 2010 (minimum of 4 years for all
patients). It was also possible to arrange an “early recall”
visit for any participant who required review outside of
his or her planned visit schedule. At each follow-up,
compliance with study treatment was reviewed, any
unexplained muscle pain and nonstudy treatment
recorded, and blood pressure measured. Samples of
nonfasting blood were taken for local laboratory assay of
CK, liver transaminases (ALT or AST), and creatinine.
Information was to be recorded about any suspected MI,
stroke, vascular procedure, cancer, or other serious
adverse event (together with the reasons for all hospital
admissions, including day cases), irrespective of compli-
ance with study treatment. If a participant became
unwilling or unable to attend his or her scheduled
follow-up visits, information about any serious adverse
events was to be obtained from them by telephone or by
direct correspondence with their own physicians until
the scheduled end of the study. Local study staff aimed to
obtain extra information from hospital records and other
appropriate sources about all reports of serious adverse
events that are of particular interest for the study aims
(ie, death, MI, angina, heart failure, stroke, transient
ischemic attack, revascularization procedure, angiogra-
phy, amputation, initiation of dialysis, kidney transplant,
cancer, myopathy, rhabdomyolysis, hepatitis, or gallblad-
der disease). This information has been sent to the
International Coordinating Centre for further review
and central adjudication in accordance with prespeci-
fied definitions by trained clinicians who are blind to
treatment allocation.
Effects of study treatment on blood lipids
The protocol specified that central analysis of blood
lipid concentrations was to be conducted on blood
samples collected from about 10% of participants at their
1- and 4-year follow-up visits and from all participants at
their 2.5-year visits, and that unblinded lipid differences
were to be periodically reviewed by the Steering
Committee to monitor study power. The sampling
procedure at 1 and 4 years was designed to ensure that
the sample was representative of the whole study
population, particularly in regard to the proportions
recruited in each country and in the proportions of
nondialysis and dialysis patients. The 1- and 4-year
samples were each collected during separate calendar
periods of approximately 6 months during the trial, with
the aim of sampling about 10% of patients from around
one third of each country's sites during those periods.
Blood samples at randomization and 1 year were available
for 787 participants (91% of those alive and selected for
sampling) and at randomization and 2.5 years from 6,632
participants (86%), with collection of 4-year samples still
in progress at the time of this report. In the case of
nonattendance when scheduled to provide a blood
sample, a patient's randomization lipid parameters were
imputed based on the assumption that the patient was
not taking study treatment at that time. Compared with
placebo, allocation to ezetimibe/simvastatin yielded
mean reductions in LDL cholesterol concentrations of
43 (SE 2.2) mg/dL at 1 year and of 33 (SE 0.8) mg/dL at 2.5
years (Table IV).
Safety of study treatment at 1 year
Because relatively little information was available about
the safety of ezetimibe at the time that SHARP was
initiated, the protocol included a simvastatin-alone arm
and prespecified that unblinded information on a limited
number of safety outcomes (but not on study outcomes)
was to be reviewed by the Steering Committee after each
patient had completed 1 year of follow-up. Compared
with the 1,054 patients who were allocated simvastatin
alone (as well as with the 4,191 patients allocated
placebo), no significant excesses were observed among
the 4,193 allocated ezetimibe/simvastatin in any of these
safety outcomes (Table V). About 10% of patients
reported muscle pain during the first year, but there
was no significant excess among the patients allocated
ezetimibe/simvastatin. Few elevations in CK to between
5× and 10× the upper limit of normal (ULN) or above 10×
ULN were observed and, again, the rates were similar in
each randomized group. There were only 7 confirmed
cases ofmyopathy (defined as CK N10× ULN plus muscle
symptoms or evidence of organ damage), 5 of which
were in patients allocated placebo, including 1 case of
rhabdomyolysis (defined as myopathy with CK N40×
ULN plus evidence of end-organ damage) in a patient
Table III. Medication use at randomization, overall and by renal
status at randomization
Not on
dialysis
On
dialysis
All
patients
Number randomized 6382 3056 9438
Antiplatelet therapy 1207 (19%) 871 (29%) 2078 (22%)
Oral anticoagulant 211 (3%) 167 (5%) 378 (4%)
ACE inhibitor 2537 (40%) 813 (27%) 3350 (35%)
Angiotensin II receptor
blocker
1657 (26%) 488 (16%) 2145 (23%)
Calcium-channel blocker 2819 (44%) 1087 (36%) 3906 (41%)
β-Blocker 2349 (37%) 1181 (39%) 3530 (37%)
Diuretic 2869 (45%) 1062 (35%) 3931 (42%)
Miscellaneous blood
pressure–lowering
drug
1201 (19%) 563 (18%) 1764 (19%)
Phosphate binder 1021 (16%) 2479 (81%) 3500 (37%)
Erythropoietin-stimulating
agent
779 (12%) 1724 (56%) 2503 (27%)
Iron-containing
preparation
845 (13%) 1319 (43%) 2164 (23%)
Vitamin D supplement 1313 (21%) 1539 (50%) 2852 (30%)
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Table IV. Biochemical efficacy at 1 and 2.5 years, by initial randomized treatment allocation
1 y 2.5 y†
Placebo
Simvastatin
only
Ezetimibe plus
simvastatin P⁎ Placebo
Ezetimibe plus
simvastatin P
Total cholesterol, mg/dL −1 (2) −36 (4) −54 (2) b.0001 −8 (1) −49 (1) b.0001
LDL cholesterol, mg/dL 1 (1) −29 (3) −42 (2) b.0001 −6 (0.5) −39 (0.6) b.0001
HDL cholesterol, mg/dL 1 (0.5) 1 (0.6) 1 (0.5) .76 0 (0.2) 1 (0.2) .21
Triglycerides, mg/dL −10 (5) −21 (8) −37 (4) b.0001 −21 (1) −45 (1) b.0001
Apolipoprotein B, mg/dL −1 (1) −22 (2) −30 (1) b.0001 −4 (0.4) −27 (0.5) b.0001
Apolipoprotein A1, mg/dL 1 (1) 5 (2) 5 (1) .01 8 (0.4) 10 (0.4) .04
Mean (SE) changes in lipids from randomization to 1-year visit in 787 patients (assuming zero change in lipids for 75 nonattendees). Changes in lipids at the 2.5-year visit are among
6632 attendees (assuming zero change in lipids for 1105 nonattendees). For triglycerides, the geometric mean percentage change in each group (and its standard error) is shown
applied to the baseline mean value. To convert milligrams per deciliter to millimoles per liter, multiply by 0.02586 for cholesterol and by 0.01129 for triglycerides; to convert
apolipoprotein A1 and B from milligrams per deciliter to grams per liter, divide by 100.
⁎ Test of difference between placebo and ezetimibe/simvastatin combination therapy, ignoring simvastatin-only group.
† Patients initially randomized to simvastatin only were to be rerandomized to ezetimibe/simvastatin combination or placebo after 1 year.
Table V. Safety at 1 year by initial randomized treatment allocation
Placebo Simvastatin only Ezetimibe plus simvastatin P⁎ P†
Number randomized 4191 1054 4193
Muscle pain 393 (9.4%) 103 (9.8%) 430 (10.3%) .19 .68
CK
N5× but ≤10 × ULN
Asymptomatic 11 (0.3%) 5 (0.5%) 16 (0.4%) .44 .88
Muscle symptoms present 3 (0.1%) 1 (0.1%) 1 (0.0%) .62 .86
N10× but ≤40 × ULN
Not on dialysis‡
No end-organ damage§
Asymptomatic 0 (0.0%) 1 (0.1%) 0 (0.0%) – .46
Muscle symptoms present 0 (0.0%) 0 (0.0%) 0 (0.0%) – –
With end-organ damage§ 4 (0.1%) 0 (0.0%) 1 (0.0%) .37 1.0
On dialysis‡
Asymptomatic 1 (0.0%) 0 (0.0%) 2 (0.0%) 1.0 1.0
Muscle symptoms present 0 (0.0%) 0 (0.0%) 1 (0.0%) 1.0 1.0
N40× ULN
Not on dialysis‡
With end-organ damage§ 1 (0.0%) 0 (0.0%) 0 (0.0%) 1.0 –
Persistently elevated liver transaminases∥ 5 (0.1%) 0 (0.0%) 7 (0.2%) .77 .39
Hepatitis¶
Infective 6 (0.1%) 1 (0.1%) 6 (0.1%) 1.0 1.0
Noninfective 1 (0.0%) 0 (0.0%) 2 (0.0%) 1.0 1.0
No cause identified 1 (0.0%) 1 (0.1%) 2 (0.0%) 1.0 1.0
Complications of gallstones
Acute pancreatitis 5 (0.1%) 0 (0.0%) 4 (0.1%) 1.0 .70
Other complications 19 (0.5%) 3 (0.3%) 17 (0.4%) .87 .77
Hospitalization with gallstones# 4 (0.1%) 4 (0.4%) 2 (0.0%) .68 .02
Pancreatitis
Acute (excluding gallstones) 7 (0.2%) 1 (0.1%) 2 (0.0%) .18 1.0
Chronic 1 (0.0%) 0 (0.0%) 0 (0.0%) 1.0 –
⁎ Test of difference between ezetimibe/simvastatin combination therapy and placebo.
† Test of difference between ezetimibe/simvastatin combination therapy and simvastatin only.
‡At the time of presentation with raised CK.
§End-organ damage is defined as acute initiation of dialysis or a N20% rise in serum creatinine. Among patients already on dialysis, it is not possible to determine if end-organ
damage has occurred.
∥At least 2 consecutive ALT or AST N3× ULN without other indication of hepatitis.
¶ Infective hepatitis—definite evidence of an infective cause; noninfective hepatitis—definite evidence of a noninfective cause; no cause identified—includes cases with negative viral
serology result and those with no viral serology result available.
#With no reported complications.
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allocated placebo (who was not taking a nonstudy
statin). No excesses were observed of persistent liver
transaminase elevations, hepatitis, gallstone complica-
tions, or pancreatitis.
Discussion
Statin therapy is now widely recommended for the
primary and secondary prevention of vascular disease
in a wide range of people,20-22 but 2 previous trials
have failed to show a clear benefit among patients
with end-stage renal failure who were undergoing
dialysis.6,7 Consequently, there remains considerable
uncertainty as to whether lowering LDL cholesterol is
of value among dialysis patients, as well as among
those with less severe renal impairment who have not
yet commenced dialysis. The SHARP trial, which has
recruited N9,000 patients with advanced CKD, 3,000
on dialysis and 6,000 not, can help to address this
clinical uncertainty.
In the International Conference on Harmonisation–
Good Clinical Practice Statistical Principles for Clinical
Trials, it is recommended that checks are made during a
trial that its actual performance has not affected statistical
power, that assumptions underlying the original design
remain plausible, and that the statistical analysis plan
remains appropriate in the light of emerging results from
other relevant trials.23 The guidelines indicate that, until
the study treatment has been unblinded, it is appropriate
to make any changes that might help the trial to provide
more reliable information about the effects of treatment.
In particular, it is stated that “The primary variable …
should be the variable capable of providing the most
clinically relevant and convincing evidence directly
related to the primary objective of the trial.”23 The
overall incidence rate for major vascular events (4.3% per
annum) in SHARP was slightly higher than had been
anticipated; but blinded central adjudication showed that
about one third of these events were noncoronary
cardiac deaths or hemorrhagic strokes, which an updated
meta-analysis of statin trials has indicated are not
prevented by LDL-lowering therapy.4 In addition, un-
blinded review of the lipid assays in SHARP showed that
the mean LDL cholesterol reduction at 2.5 years (ie, at
about the midpoint of the trial) was 33 mg/dL, rather than
the anticipated difference of 39 mg/dL. Based on the
larger-than-expected proportion of major vascular events
that were nonatherosclerotic (and so not likely to be
reduced by LDL-lowering therapy) and the smaller-than-
expected reduction in LDL cholesterol, a relative risk
reduction of 13% in the original primary outcome of
major vascular events may be all that can realistically
be expected. Table VI indicates that SHARP would have
only 66% power at P = .01 (2-sided) to detect such a
difference among the ~8400 patients initially randomized
to ezetimibe/simvastatin versus placebo (Arm 2 versus
Arm 1 in Figure), which is the population specified in the
protocol for the primary comparison.
SHARP is overseen by an independent Steering Commit-
tee that includes nephrologists, cardiologists, clinical
trialists, and statisticians, with 2 nonvoting observers
from the funder. The independent sponsor is the
University of Oxford, and the trial is funded by the
supplier of the study drugs (Merck & Co). Changes to the
study plans in response to a revision of the underlying
sample size assumptions are entirely appropriate provided
that care is taken to avoid bias by, as in the case of SHARP,
remaining blind to the effects of study treatment on the
efficacy outcomes.23,24 Consequently, in October 2009,
the Steering Committee decided to change the primary
outcome to major atherosclerotic events, defined as the
combination of MI, coronary death, ischemic stroke, or
any revascularization procedure (ie, exclusion of noncor-
onary cardiac deaths and strokes confirmed to be
hemorrhagic from the original major vascular event
outcome). A relative risk reduction of 18% in this revised
outcome seems realistic, and Table VI shows that SHARP
has good statistical power to detect such an effect among
the 8,400 patients initially randomized to ezetimibe/
simvastatin versus placebo. Moreover, because even better
power can be achieved by including those patients who
were randomly allocated between ezetimibe/simvastatin
versus placebo following allocation to simvastatin for 1
year (ie, arm 3b vs 3a in Figure 1), the Steering Committee
decided that the main comparisons should include them.
These and other changes are described in the revised
statistical analysis plan for SHARP (online Appendix A).
The independent sponsor is required by its contract
with the funder to seek its formal agreement to any
protocol change, but the funder declined to approve the
changes agreed by the Steering Committee. Although it is
not possible to revise the protocol accordingly, the
Steering Committee is free to change the statistical
analysis plan as it considers appropriate while it remains
blind to the effects of treatment on efficacy end points.
Table VI. Improvement in study power by changing to new
primary outcome comparison
Outcome
Anticipated
proportional
reduction⁎ n†
Expected
result (active
vs placebo)‡
Power at
2P = .01
Original
primary
13% ~8400 737 versus 845 66%
13% ∼9400 807 versus 927 72%
New
primary
18% ~8400 525 versus 639 84%
18% ∼9400 576 versus 701 88%
⁎ Treatment effects estimated using data from the Cholesterol Treatment Trialists
Collaboration.4
†Sample size is increased from ~8400 to ∼9400 by the inclusion of participants
randomized to simvastatin only for the first year and subsequently randomized to
ezetimibe/simvastatin versus placebo. For these participants, events are only counted
in the primary outcome if they occur after the second randomization.
‡Based on blinded outcome event rates in November 2009.
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The present report and related appendices are, therefore,
intended to record that the chief emphasis for evaluating
the efficacy of study treatment in SHARP will now not be
on the primary outcome in the protocol of major vascular
events, but will instead be on the new key outcome of
major atherosclerotic events. This change of emphasis
should help to reduce the risk of a false-negative result (in
which a potential beneficial effect on atherosclerotic
outcomes is diluted by a lack of benefit on nonathero-
sclerotic components), a scenario that would have
adverse consequences for patients.
During the conduct of SHARP, an unexpected concern
was raised by the SEAS placebo-controlled trial of
ezetimibe 10 mg plus simvastatin 20 mg daily among
1,873 people with moderate aortic stenosis about an
apparent excess risk of cancer (105 on ezetimibe plus
simvastatin vs 70 on placebo, P = .01).25 The SHARP
investigators received agreement from its Data Monito-
ring Committee to access unblinded data on incident
cancers (but no other clinical events), as did the
investigators for IMPROVE-IT, which is comparing
simvastatin plus ezetimibe versus simvastatin among
18,000 patients with acute coronary syndrome.26 When
these interim data on cancer were examined together in a
meta-analysis,27 they did not provide support for the
hypothesis that ezetimibe might cause cancer; and their
Data Monitoring Committees recommended that each
trial continue. Completion of SHARP in 2010 (and,
subsequently, of IMPROVE-IT in 2013) will provide
additional evidence about the effects on cancer and
other nonvascular outcomes of adding ezetimibe to
simvastatin (which has been shown on its own to be
safe in large-scale trials3,4).
In conclusion, SHARP has randomized 9,438 patients
with CKD to receive LDL-lowering therapy or placebo for
an average of about 4.4 years. Final follow-up will be
completed by August 2010, and the results will be
presented by the end of the year. As described above, the
chief emphasis will be on the revised outcome of major
atherosclerotic events (and not on the protocol-defined
outcome of major vascular events), although results will
also be presented for the original primary and other
efficacy and safety outcomes.
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Appendix A. Statistical Analysis Plan for
SHARP (finalized on August 20, 2010;
blind to results by allocated
treatment for clinical outcomes)
Introduction
In accordance with the guidance provided by ICH-GCP
Statistical Principles for Clinical Trials,23 checks have been
made during the SHARP trial to ensure that statistical
power has been maintained and that assumptions
underlying the original design remain plausible. Review of
the unblinded lipid assays during SHARP showed that the
mean LDL cholesterol reduction at 2.5 years (ie, at about
the midpoint of the trial) was 33 mg/dL (0.85 mmol/L)
rather than the anticipated difference of 39 mg/dL (1
mmol/L), and review of blinded data on clinical outcomes
showed that about one third of the original protocol-
defined primary outcome of major vascular events
(defined as cardiac death, MI, any stroke, or any
revascularization procedure)28 among the CKD patients
in SHARP are noncoronary cardiac deaths or hemorrhagic
strokes, which have been found in other trials not to be
prevented by statin therapy.4 Consequently, in October
2009, the Steering Committee decided (blind to the
effects of study treatment on clinical outcomes) to make a
number of changes in the plans for analyses in order to
ensure that SHARP remains sensitive to any benefits on
atherosclerotic outcomes that may exist.
The main change was to place the chief emphasis on
“major atherosclerotic events,” defined as the combi-
nation of coronary death, MI, ischemic stroke or any
revascularization procedure (ie, excluding noncoronary
cardiac deaths and strokes confirmed to be hemor-
rhagic) rather than on major vascular events. Conse-
quently, although an analysis of major vascular events
will be provided, the chief emphasis will be on the
analyses of major atherosclerotic events among all of
the patients randomized to ezetimibe/simvastatin versus
placebo at any time point (ie, Arm 2 plus 3b vs Arm 1
plus 3a, see Figure 1 of the main article). This should
help to reduce the possibility of a false negative result
by ensuring that a potential beneficial effect on
atherosclerotic outcomes is not diluted by a lack of
benefit on nonatherosclerotic components.
Comparisons of ezetimibe/simvastatin versus
placebo. The prespecified comparisons involve “inten-
tion-to-treat” analyses among all of patients ever ran-
domized to ezetimibe/simvastatin versus all patients
allocated to placebo, with stratification by whether
patients were initially allocated simvastatin for 1 year
(Arm 3b vs Arm 3a) or not (Arm 2 vs Arm 1).
Key outcome. The chief emphasis will be on the
effects of ezetimibe/simvastatin on the overall incidence
of first major atherosclerotic event (ie, coronary death,
MI, ischemic stroke, or any revascularization procedure).
Subsidiary outcomes. In support of the analyses of
major atherosclerotic events, analyseswill be conducted of:
• the original protocol-defined primary outcome of
major vascular events (ie, cardiac death, MI, any
stroke, or any revascularization), which will also be
analysed separately (as in the original protocol) for
Arm 2 versus Arm 1;
• the separate components of major atherosclerotic
events:
○ major coronary events (coronary death or nonfatal MI)
○ ischemic stroke
○ coronary or noncoronary revascularization (ex-
cluding dialysis access procedures)
The main renal outcome will be end-stage renal
disease, which is defined as commencement of long-
term dialysis or transplantation among patients not on
dialysis at the time of randomization to ezetimibe/
simvastatin versus placebo.
Tertiary outcomes and comparisons. It is not
anticipated that SHARP will have good power to explore
subgroup effects reliably, but tertiary comparisons will
assess whether there is definite evidence of variations in
the effects of ezetimibe/simvastatin on major atheroscle-
rotic events in different subgroups, based on character-
istics at the time of randomization to ezetimibe/
simvastatin versus placebo:
• patients who were receiving dialysis and those who
were not
• patients with evidence of pre-existing atherosclerotic
disease, including: coronary disease (ie, angina);
peripheral arterial disease; cerebrovascular disease;
at least one of these 3 conditions; none of them
• diabetes and no diabetes
• men and women
• age: 40 to 49, 50 to 59, 60 to 69, ≥70
• smokers and nonsmokers
• diastolic blood pressure: b80, 80 to 89, 90 to 99,
≥100 mm Hg
• systolic blood pressure: b140, 140 to 159, 160 to 179,
≥180 mm Hg
• approximate tertiles of lipid parameters: total
cholesterol, LDL-cholesterol, HDL cholesterol, non-
HDL cholesterol, triglycerides, apolipoprotein B,
apolipoprotein A1
• approximate tertiles of body mass index, waist
circumference, hemoglobin, plasma albumin, plasma
phosphate
• use of particular drugs, including antiplatelet
therapy, oral anticoagulants, angiotensin-converting-
enzyme inhibitor or angiotensin-receptor blocker,
β-blocker, calcium-channel blocker, diuretic, eryth-
ropoietin, sevelamer
Subgroup comparisons of the effects on major athero-
sclerotic events will also be conducted separately among
SHARP Collaborative Group 794.e1
American Heart Journal
Volume 160, Number 5
patients who, at the time of their randomization to
ezetimibe/simvastatin versus placebo, were:
(i) on dialysis, subdivided by:
• hemodialysis and peritoneal dialysis
(ii) not on dialysis, subdivided by:
• GFR estimated from modified diet and renal
disease equation:18 ≥60, 30 to 59, 15 to 29,
b15 mL/min/1.73 m2
• approximate tertiles of cystatin C
• normoalbuminuria; microalbuminuria; macroal-
buminuria (based on urinary albumin-creatinine
ratio)
In addition, subgroup analyses will assess whether the
effects on end-stage renal disease of ezetimibe/simvasta-
tin vary according to baseline renal function. Progression
to end-stage renal disease is rapid when GFR is already
below 15 mL/min per 1.73 m2 (ie, Kidney Disease
Outcomes Quality Initiative19 stage 5 CKD), so even a
large proportional reduction in the rate of progression
might result in only a short delay before commencing
dialysis. By contrast, for patients with stage 3 CKD (ie,
GFR 30-60 ml/min per 1.73 m2), a small proportional
reduction in the rate of progression might correspond to
a delay of some months. Hence, exploratory analyses
among patients presenting at different stages of CKD will
compare both proportional and absolute effects of
allocated treatment on the slope of estimated GFR over
time and, separately, on the need for dialysis or
transplantation.
Tertiary comparisons will also examine the effects of
ezetimibe/simvastatin on:
• mortality, both overall and within particular cate-
gories of causes of death: cardiac (coronary, other
cardiac), stroke (ischemic, hemorrhagic and un-
known type), other vascular, neoplastic, renal, other
and unknown causes
• cancers, subdivided by site (in categories previously
defined in a published interim analysis of SHARP
cancers,27 with appropriate statistical adjustment for
multiplicity), and excluding any recurrences of
cancers known to be present prior to randomization
to ezetimibe/simvastatin
• stroke, both overall and subtypes (ischemic, hemor-
rhagic, and unknown)
• transient ischemic attacks
• hospital admission for angina and, separately, for
heart failure
• development of diabetes among patients who were
not known to have it at the time of randomization to
ezetimibe/simvastatin
• revision of vascular access for dialysis
• end-stage renal disease or death from any cause and,
separately, doubling of plasma creatinine or end-
stage renal disease (among those not on dialysis at the
time of randomization to ezetimibe/simvastatin).
Additional safety outcomes. In addition to assessing
the effects of allocation to ezetimibe/simvastatin on the
efficacy and safety outcomes listed above, assessments
will be made on:
• muscle-related outcomes:
○ muscle pain or weakness
○ elevations of creatine kinase: N5 but ≤10 × ULN,
N10 and ≤40 × ULN, and N 40 × ULN; subdivided
into those: without symptoms, with symptoms but
no evidence of end-organ damage, with symptoms
and evidence of end-organ damage, with symp-
toms among dialysis patients (when end-organ
damage cannot be assessed)
• Liver-related outcomes:
○ hepatitis, subdivided into: infective (definite evi-
dence of an infective cause), noninfective (definite
evidence of a non-infective cause), no cause
identified (eg, negative viral serology or no
serology available)
○ persistently elevated liver transaminases (at least 2
consecutive alanine or aspartate transaminase N3 ×
ULN without other indication of hepatitis)
• complications of gallstones: acute pancreatitis with
gallstones; cholelithiasis requiring hospital admis-
sion; other complications of gallstones
• pancreatitis (without gallstones): acute pancreatitis;
chronic pancreatitis.
Details of analyses
Analysis of efficacy and safety outcomes. The
analyses will involve comparisons of ezetimibe/simvasta-
tin versus placebo during the period for which patients
were scheduled to take study medication, irrespective of
compliance (ie, “intention-to-treat” analyses29,30). Analy-
ses will be based on the first relevant un-refuted event,
that is, an event of a particular type will be included in an
analysis provided that it has either been confirmed or has
not been refuted during the adjudication process. In
particular, outcomes that involve MI will include definite,
probable and possible cases.
Time-to-event analyses will use log-rank methods29,30 to
calculate average event rate ratios, confidence intervals,
and two-sided P values. All analyses will be stratified by
whether patients were originally randomized to ezeti-
mibe/simvastatin versus placebo (Arm 2 vs Arm 1) or
were re-randomized after about 1 year on allocated
simvastatin (Arm 3) to ezetimibe/simvastatin versus
placebo (Arm 3b vs Arm 3a). Log-rank observed (O)
minus expected (E) values and their variances will be
calculated for each of the two strata, and the overall log-
rank statistic derived as the sum of the log-rank statistics
for the 2 strata. The variance for the overall log-rank
statistic is the sum of the variances of the log rank (O-E)
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for each stratum. The overall log rank (O-E) and its
variance will be used to derive the stratified odds ratio, its
confidence interval, and 2-sided P value.29,30
Tests for heterogeneity of effects. The large number
of major atherosclerotic events expected in this study
may allow direct assessment of the effects of treatment in
some subcategories of patient (eg, baseline levels of LDL
cholesterol). However, when a number of different
subgroups are considered, chance alone may lead to
there being no apparent effect in several small subgroups
in which the effect of treatment really is about the same
as is observed overall. In such circumstances, “lack of
direct evidence of benefit” is not good “evidence of lack
of benefit,” and clearly significant overall results would
provide strong indirect evidence of benefit in some small
subgroups where the results, if considered in isolation,
are not conventionally significant (or, even, perhaps,
adverse).29–31 Hence, unless the proportional effect in
some specific subcategory is clearly different from that
observed overall, the effect in that subcategory is likely to
be best estimated indirectly by applying the proportional
effect observed among all patients in the trial to the
absolute risk of the event observed among control
patients in that category.29,30 Tests for heterogeneity of
the proportional effect on particular outcomes in specific
subgroups will be used (with allowance for multiple
comparisons and other differences between subgroups)
to determine whether the effects in those subgroups are
clearly different from the overall effect.29,30 If, however,
such subgroups can be arranged in some meaningful
order (eg, baseline renal function) then assessment of any
linear trend in the proportional effects on outcome will
be made instead. Baseline status of patients will be as
measured at the time of their randomization to ezetimibe/
simvastatin versus placebo (so, for patients in arm 3, their
baseline characteristics will, wherever possible, be
updated to reflect their status when re-randomized).
Allowance for multiplicity of comparisons. The
key analysis of major atherosclerotic events and the
subsidiary analysis of major vascular events (the original
primary outcome) will be performed without adjustment
for multiplicity. The subsidiary analyses of the separate
components of major atherosclerotic events will be
assessed with appropriate adjustment for multiplicity
using the Hochberg procedure.32 For the interpretation
of tertiary comparisons, allowance will be made for
multiple hypothesis testing,29,30 taking into account the
nature of events (including timing, duration and severity)
and evidence from other studies. In addition to the
prespecified comparisons, many other analyses will be
performed, with due allowance for their exploratory and,
perhaps, data-dependent nature. Conventionally, 2-sided
P values b.05 are described as “significant.” However, the
larger the number of events on which a comparison is
based and the more extreme the P value (or, analogously,
the further the lower limit of the confidence limit is from
the null hypothesis) after allowance has been made for
the nature of the particular comparison (ie, primary,
secondary or tertiary; prespecified or exploratory), the
more reliable the comparison and, hence, the more
definite any finding should be considered.
Analyses of biochemical efficacy. Biochemical
efficacy samples were scheduled to be taken from 10%
of the study population at their 1- and 4-year follow-up
visits and from all patients at their 2.5-year visits.
Absolute changes in plasma lipids between randomiza-
tion and follow-up are calculated for each patient, with
zero change assigned to anyone selected for blood
sampling who was alive at the time of the follow-up
assessment but failed to provide a sample for any reason
(since such patients are likely to have discontinued
treatment). Student’s t test will be used to compare the
mean changes observed in the ezetimibe/simvastatin and
placebo groups.
Health economic analyses. For the purposes of
within-trial economic analyses and assessment of health-
care resource utilization, a summary of all major vascular
events, cardiac events, revascularization procedures
(coronary or noncoronary), deaths, onset of end-stage
renal disease, hospital admission for angina, and hospital
admission for heart failure will be derived. A separate
analysis plan for determining the costing of these events,
sensitivity analyses, subgroup analyses, variance estima-
tion, and statistical testing for treatment comparisons will
be developed. In addition to the within-trial analyses,
survival analyses will be used to generate a prediction
model for the projection of events beyond the trial
treatment period and evaluation of the lifetime cost-
effectiveness of ezetimibe/simvastatin.
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nonvoting statisticians to the DMC: R Peto, J Emberson,
S Parish.
International Coordinating Centre, CTSU, University
of Oxford
Senior management team: C Baigent, C Bray, C Knott,
M Landray; Administration: T Bahu, E Booth-Davey,
A Brewster, F Yau, E Denis, K Frederick, D Haywood, J
Heineman, S Howard, K Jayne, Z Madgwick, S Michell,
K Murphy, L Ning, J Nolan, M Nunn, J Roberts,
M Wickman; Clinical support and outcome adjudication:
L Bowman, R Bulbulia, T Dasgupta, R Haynes,
W Herrington, D Lewis, M Mafham, W Majoni, K Rahimi,
N Rahman, C Reith; Computing: R Ait-Sadi, I Barton,
A Baxter, A Young, W Zhu; Laboratory: M Hill, S Clark,
K Kourellias, M Radley; Monitoring: K Brown,
D Worthing; Statistics: J Emberson; Validation: G Coates,
B Goodenough, N Lucas.
Regional and National Coordination
Australia: The George Institute for International Health,
Sydney: B Neal, A Carreras, A Cass, R Currie, O
Donaldson, E Fjalling, M Gallagher, K Gibson, J Goddard, J
Healy, L Hones, M Jardine, I Kwong, C Lee, M Merai, S
Murray, V Perkovic, A Rendina.
Austria: AllgemeinesKrankenhausWien, Vienna:MHaas.
Canada: St Paul's Hospital, Vancouver: A Levin; London
Health Sciences Centre, Ontario: K Gallo; Penticton
Regional Hospital: S Caron; St Paul's Hospital, Vancouver:
K Carlson, K Foley, S Matzek, L Mewhort, S O'Donoghue,
A Perel-Winkler, T Terins.
China: Fuwai-Oxford Collaborative Centre for Cardio-
vascular Health, Beijing: L Jiang; CTSU, University of
Oxford: Y Chen, Z Chen, Q Nie, H Yu; Fuwai-Oxford
Collaborative Centre for Cardiovascular Health, Beijing:
L Ge, D Hao, L Li, X Pang, X Wei, G Yan.
Czech Republic: Charles University, Prague: V Tesar,
V Certikova Chabova.
Denmark: H:S Rigshospitalet, København Ø: B Feldt-
Rasmussen; Smerud Medical Research Denmark,
Brøndby: H Holst, T Mølvadgaard, D Munksgaard.
Finland: Helsinki University Hospital: CGrönhagen-Riska;
Smerud Medical Research Finland, Espoo: Y Peltonen.
France: Centre de Recherche Clinique, et Services de
Pharmacologie Clinique et de Néphrologie, Amiens:
Z Massy; Centre de Recherche Clinique, et Service de
Pharmacologie Clinique, Amiens: S Liabeuf; Direction de
la Recherche clinique, Amiens: C Lebel, L Ouabou.
Germany: Universitätsklinikum Würzburg and Zentrale
für Klinische Studien am Klinikum: B Bauer, K Bergmann,
M Beusch, D Cavitt, C Drechsler, I Dulau, K Hügen, V
Krane, S Kempf, B Kuchenmeister, S Küllmer, V Pscheidl,
D Schmiedeke, M Schwarz, K Speerschneider, B Stahl,
C Wanner.
Malaysia: Hospital Sultanah Aminah, Johor Bahru:
L S Hooi; Clinical Research Centre, Kuala Lumpur:
BC Lim, Nadia H, Zishareena M F, S Vasuthavan; Klinsel
Sdn Bhd, Kuala Lumpur: AT Ganesapillai, S Yuen.
Netherlands: Julius Centre for Health Services and
Primary Care, Utrecht: D Grobbee, I Bobbink, K Groot,
I Sikking; University Medical Center Groningen, Univer-
sity of Groningen: D de Zeeuw.
New Zealand: Dunedin Hospital: R Walker; The George
Institute for International Health, Sydney: J Raley.
Norway: Rikshospitalet Universitetssykehus, Oslo:
H Holdaas; Smerud Medical Research Norway, Oslo:
M Colban, K Smerud, N Trygg, E Waagaard, H Westad.
Poland: Fundacja Dializa by Katedra i Klinika Nefrologii
Endokrynologii i Ch, Katowice: A Wiecek, S Rotkegel,
U Spiechowicz; Smerud Medical Research Poland,
Warsaw: M Domoradzka, M Gawłowska.
Sweden: Njurmedicin, Medicincentrum, Uppsala:
B Fellström; Smerud Medical Research Sweden, Uppsala:
A Flygar, I Ödmark, A Pettersson.
Thailand: Maharaj Nakorn Chiang Mai Hospital:
V Ophascharoensuk; Rajavithi Hospital, Bangkok:
U Krairittichai.
United Kingdom: Royal Free Hospital, London:
D Wheeler; Addenbrokes Hospital, Cambridge:
S Blackwood; CTSU, University of Oxford: J Barclay,
J Benham, R Brown, L Cureton, D Jackson, I Kennedy,
C Leaper, A Taylor, C Winter, C Wise; Leighton Hospital,
Crewe: M Nash; Macclesfield Hospital: A Taylor Bennett;
Princess Royal Hospital, Telford: D Donaldson; Queen
Margaret Hospital, Dunfermline: K Chalmers; Southmead
Hospital, Bristol: H Corderoy.
USA: Hennepin County Medical Centre, Minneapolis:
B Kasiske; Berman Center for Clinical Research,
Minneapolis: M Bartkoske, C Bjerk, A Camarena,
R Grimm, L Herskovitz, C Heuer, J Levin, R Robinson,
B Wicklund; Boston VAMC: D Bentzel, S Cohen,
C Costa, M Gaziano, R Scranton.
Local Clinical Centres
Australia
Albury Base Hospital: R Auwardt, M Boyer, P Cogdell, K
Gibson; Alfred Hospital, Melbourne: S Menahem, J
Sheldrake; Austin Health, Melbourne: P Mount, M
Fraenkel, P Bisscheroux, J Dempester, P Gleeson; Bend-
igo Health Care Group: G Harris, C Holmes, K Hyett, A
Linton; Bundaberg Base Hospital: P Miach, D Booth, L
Druce; Cairns Base Hospital: M Mantha, E Borg, S Green, J
Killen, Y Lynch; Core Research Group Pty Ltd, Milton: D
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Colquhoun, K Herzig, G Row, J Addison, J Asa, G Beatson,
D Calvird, J Edmunds, A Ferreira-Jardim, A Gwynne, D
Mackay, L McLoughlin, C Wightwick, L Williams;
Fremantle Hospital: P Ferrari, J Barry, S Hodson, W
Zakrzewska; Gold Coast Hospital: E Meagher, M Mulcahy,
A Parnham; John Hunter Hospital, Newcastle: S Carney, L
Garvey, A Gillies, S Hayes; Launceston General Hospital:
M Mathew, R Fassett, L Anderson, C Clingeleffer, A
Curnock, L Mayne, D Richardson, M Smith, S Smith;
Liverpool Hospital: M Suranyi, K Howlin, J Chow, B
Cleland, G Rayment, T Spicer, J Wong, M Wong;
Melbourne Renal Research Group: D Packham, C Alison, I
Fraser, J Mitchell, J Nagle; Monash Medical Centre,
Clayton: F Brown, C Ellery, J Monkhouse, J Nandkumar, L
Reith-Myers; Nambour General Hospital: N Gray, C Cocks,
M Courtney, P Hollett, C Johnston, H Larsen, S Murray, A
Pollock, S Stewart, G Styles; Nepean Hospital, Penrith: R
Wyndham, M Fanning, W Gibson, S Jackson, M Manner-
ing, E Mercado, R Oliphant, K Sud, N Ubera, C Wood;
Peninsula Clinical Research Centre, Queensland: J
Karrasch, T Brinkley, K Estensen, A Moroney, J Sutton, R
Warren; Pine Rivers, Chermside: D Saltissi, H Jahke, H
Roach, J Saltissi (Cockayne), M Wiederroth O'Brien;
Princess Alexandra Hospital, Woolloongabba: D Johnson,
V Bali, J Edmunds, M Evans, K Franzen, S Halbish, J
Helyar, A Martin, D Mudge, K Sonnenburg, J Sudak; Renal
Research, Gosford: S Roger, S Almeida, H Andrews,
L Bohringer, L Bouwhuis, L Brady, A Carpenter, S Warren;
Royal Adelaide Hospital: T Elias, K Bannister, G Chew,
J Clarke, R Faull, A Hooper, L Jeffs, A Napier, C Peh, K
Pirone, F Skilton; Royal Brisbane Hospital: D Ranga-
nathan, J Best, L Hart, H Healy, C Morgan, S Ratanjee,
A Salisbury; Royal Hobart Hospital: M Jose, J Freeman,
R Hamilton, G Kirkland, G Read; Royal Melbourne
Hospital: R Walker, V Perkovic, H Anderson, K Boekel,
M Farrell, A Foreman, K Iliev, E Pedagogos, T Raspudic;
Royal North Shore Hospital, St Leonards: C Pollock,
B Cooper, J Kesselhut, C Macadam, J Pearse, C Rowland,
H Tully; Royal Perth Hospital: A Irish, G Dogra, P Coutts,
L Hayes, D Khoo, B Nathoo, K Shakespeare, A Warger;
Royal Prince Alfred Hospital, Sydney: A Gillin, J Burman,
C George, S Sherwood, P Snelling, C Stevens; Sir Charles
Gairdner Hospital, Perth: B Hutchison, G Luxton, J Barry,
N Devenny, L Hayes, H Herson, S Pellicano; St George
Hospital, Kogarah: J Kelly, J Coutelas, C Garlinge,
A McClelland, S Pirabhahar, H Saleh; St Vincent's Hospital,
Fitzroy: R Langham, B Englebright (Joseph), M Giang,
M Lanteri, K Mullins, C Turner; Sydney Adventist
Hospital: P Collett, S Stokoe, K Sutherland, D Talafua; The
Canberra Hospital: G Talaulikar, A Clarkson, M Gallagher,
C Rees, G Carney, M Falk, D Gracey, A Jadeer, P Johnson,
K Karpe, R Singer, G Walters; The Queen Elizabeth
Hospital, Adelaide: S McDonald, J Burgess, K Fischer,
M Gentgall, M Hockley, D Veitch; The Townsville
Hospital: P de Jersey, A Gillam, V Hartig, K Holland,
J McArdle, WWashington; Westmead Hospital: G Rangan,
M Mikaheal, P Murie, N Perez, N Punnoose,
T Smolonogov, N Taler, G Williams; Wollongong
Hospital: C Wen, J Kohlhagen, J Wessels, S Johnson,
A Reid, J Ryan, D Taprell.
Austria
Allgemeines Krankenhaus Wien: M Haas, M Auinger,
M Eigner, K Kodras, C Leithner, L Magpantay, C Marterer,
R Prager, C Prinz; Klinikum Wels-Grieskirchen:
E Seiringer, R Kramar, E Mitter, H Stummvoll,
G Dieplinger, Krankenhaus Zell am See: R Wenzel, G
Stolz, S Dröse, E Edlinger, E Headlam-Leitner, H Miska, M
Then, S Weninger; Landeskrankenhaus Feldkirch: K
Lhotta, U Neyer, H Dickie, S Smodek, H Sprenger-Mähr;
Universitätsklinik für Innere Medizin Innsbruck: A
Rosenkranz, E Zitt, B Mayr, A Schinner.
Canada
Charles LeMoyne Hospital, Greenfield Park: G Soltys,
V Bégin, S Brunet, S Cournoyer, M Gelinas, C Giroux,
J Martineau, M Roy, L Savoie; CHUQ-Hotel Dieu de
Quebec: M Agharazii, J Blouin, S Desmeules, S Langlois,
F Samson; Credit Valley Hospital, Mississauga: G Wong,
L Constantini, J Jing, J Malko, C Rivers, D Rochester,
C Skilling, A Wadgymar, G Wu; David M Kates Medical
Services Inc Kelowna: D Kates, J Husch, M Mantle,
L Turri; Eastern Regional Health Authority, Newfound-
land: B Barrett, B Curtis, B Greeley, M Hannaford,
J Harnett, M Kelly, E Langille, J Morgan, S Murphy; Fraser
Health Authority, Vancouver: M Karim, T Arbo,
G Carpenito, A Cass, V Chan, G DaRoza, K Foley,
M Friesen, D Kraus, S Lam, B Lange, S Minhas, R Starko,
S Torng, K Vela; Hôpital du Sacré-Coeur de Montréal:
F Madore, P Roy, S Troyanov; Hopital Maisonneuve-
Rosemont, Montréal: A Bonnardeaux, L Lauzon,
V Pichette; Kingston General Hospital/Queen's
University: K Yeates, K Mahoney, C Myers, R Pilkey;
London Health Sciences Centre: L Moist, M Edgar,
K Gallo, A House, C Kortas, S Mindorff; OTT Healthcare
Inc Scarborough: P Tam, S Chow, J Fung, G Nagai, P Ng,
D Rochester, T Sikaneta, R Ting; Penticton Regional
Hospital: B Forzley, S Caron, Y Clouatre, S Cooper,
H DaCosta, S Granger, S Valley; Regina Qu'Appelle Health
Region: S Karunakaran, M Abdulhadi, C Altwasser,
S Anderson, L Bergquist; Royal Inland Hospital,
Kamloops: C Wijeyesinghe, L Berst; Royal Jubilee
Hospital, Victoria: K Horgan, K Coles, T Lotter, L Robson;
Royal Victoria Hospital, Montreal: P Barre, J Golden,
M Golden, N Tanguay; St Boniface General Hospital,
Winnipeg: C Rigatto, S Armstrong, A Fine, B Fontaine,
D Friesen, S Henry, M Kraushar, M Reslerova, M Verrelli;
St Joseph's Healthcare, Hamilton: C Rabbat, C Clase,
G Suva, N Winegard; St Michael's Hospital, Toronto:
M Goldstein, S Curvelo, S Donnelly, J Huckle, R
Marticorena; St Paul's Hospital, Vancouver: A Levin,
C Chan-Yan, A Chiu, L DeLuca, D Flamer, K Foley, J Gill,
A Jamal, B Jung, M Kiaii, D Kraus, D Landsberg, S Minhas,
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A Perel-Winkler, N Rozen, P Taylor, K Vela, R Werb;
St Paul's Hospital Saskatoon: G Pylypchuk, A Ahmed,
J Barton, M Hundseth, J Kappel, I Keindel, J Klassen,
S Pylypchuk, M Rindall; Sunnybrook Health Sciences
Centre, Toronto: S Tobe, D Naimark, M Agelopoulos,
M Chessman, M Hladunewich, N Perkins, S Sainsbury;
Thunder Bay Regional Health Sciences Centre:
W McCready, B Adams; University of Alberta Hospital:
M Tonelli, S Caldwell, U Kumar, A McMahon, S Nikitin,
J Restall, S Treit, Y Wysocki; Vancouver General Hospital:
J Duncan, M Copland, J Jastrzebski, P Keown, S Kwan,
A Levin, D Rogers, J Shapiro, S Singh, L Sioson, K Yee,
C Yeung; Winnipeg Health Sciences Centre: J Zacharias,
J Bueti, B Dizon, H Lam, L Miller, M Ross, M Zarrillo.
China
Baotou Medical College First Affiliated Hospital, Inner
Mongolia: Z Li, C Wang, L Liu; General Hospital Of
Shanyang Army, PLA of China, Liaoning: M Hong,
H Zheng, W Zuo; Inner Mongolia Baogang Staff Hospital:
Z Ge, Q Liu, Y Li; Inner Mongolia Baotou City Central
Hospital: K Sun, R Zhao; Inner Mongolia Electrical Power
Central Hospital: G Sun, F Wang; Inner Mongolia
Hulunbeiermeng Hospital: Z Cui; Jilin Province Jilin City
Central Hospital: L Liu, F Lou; Jilin Provincial Hospital:
Y Du, L Song, H Huang; Lanzhou University Second
Affiliated Hospital: Z Song, J Wang, L Zhou; Liaoning
Angang Lishan Hospital: R Wu, R Xiao, Q Zhang;
Liaoning Provincial People's Hospital: N Duan, N Ju, Z Li;
PLA 306 Hospital, Beijing: A Wang, Z Xu, Z Lu;
Shangdong Weifang People's Hospital: Y Zhang, L Zhao;
Shenyang Fourth People's Hospital: Y Li, C Zhang; The
Third Xiangya Hospital of Central South University,
Hunan: Z Mo, Y Xie, J Xiong; Wuhan City Central
Hospital: J Chen, L Guo, S Zhao.
Czech Republic
Charles University, Prague: M Peiskerova, E Jancova,
M Kazderova, L Kobrova; Csl Armady 1076-HDS
Eurocare, Usti nad Orlici: P Gorun; FNKV-Fresenius
Dialysis Unit, Prague: T Kmentova; Institute for Clinical
& Experimental Medicine IKEM, Prague: M Burgelova,
L Lyerova, O Viklicky; Kukucinova-Fresenius Dialysis
Unit, Prague: M Berdych; Nemocnice Strakonice-dialyza:
Z Nydlova, G Jelinkova, J Moltaš; Nemocnice, Jihlava:
T Pauzar, P Knetl, J Cahova, J Simkova, M Zakova;
Nusle-HDS Eurocare, Prague: S Vankova, R Safarova;
Parallel 50-HDS Eurocare, Prague: M Hruby, R Karlova,
V Prikaska, P Sellenberg; Plzen-HDS Eurocare: E Vesela,
L Malanova; Sokolov-Fresenius FMC Dialysis Unit:
J Vlasak, P Kaprova, D Novakova; Teplice-HDS Euro-
care: K Kotherova, M Studenovska.
Denmark
Aalborg Sygehus Syd: J Christensen, J Sølling, M Jepsen,
V Kristensen; H:S Rigshospitalet, København Ø: B Feldt-
Rasmussen, H Aerenlund, M Bræmer-Jensen, A Kamper,
S Raaschou; Herlev Hospital: J Heaf, J Dreyer, P Freese,
M Holm, M Munch; Hillerød Sygehus: E Gade-Rasmussen,
K Bredmose, H Daugaard; Holbæk Sygehus: J Nielsen,
M Friedberg, D Jensen, M Munk Plum, K Sølling; Odense
Universitetshospital: H Dieperink, L Arp Nielsen,
E Friborg, A Gløe-Jakobsen, P Thye Rønn; Roskilde
Sygehus: K Rasmussen, C Andersen, A Johansen, L Ødum,
O Østergaard, L Pedersen; Sønderborg Sygehus, Odense
C: H Dieperink, S Lykkegaard, M Aundal, L Arp Nielsen,
S Faureholm Huess, P Freese, E Friborg, A Gløe-Jakobsen;
Viborg Sygehus: H Danielsen, J Madsen, M Nyvang.
Finland
Helsinki University Hospital: A Ekstrand, H Boman,
J Hartman, A Lipponen, R Lithovius, V Rauta, A Salmela,
K Saloranta; Keski-Suomen Central Hospital, Internal
Medicine Clinic, Jyväskylä: T Forslund, P Koskiaho;
Pohjois-Karjala Central Hospital, Internal Medicine
Department, Joensuu: K Jääskeläinen, M Kanninen;
Satakunta Central Hospital, Pori: K Laine, M Asola,
J Huhti, M Pentti; Turku University Hospital:
K Metsärinne, M Heiro, N Koivuviita, M Saarinen, R Tertti.
France
Amiens: Z Massy, G Choukroun, A Fournier, S Liabeuf,
L Ouabou; Besancon: D Ducloux, F Marechal, D Simula
Faivre; Bordeaux: C Combe, M Douillet, T Lamblot,
H Nardi, B Vendrely; Brest: B Bourbigot, S Ferlandin;
Grenoble: P Zaoui, C Jouet; Harfleur-Clinic du Petit
Colmoulins: S Geffroy-Guiberteau, L Bugnazet; Limoges:
J Aldigier, C El Hamel-Belili, S Giraud; Marseille: B Dussol,
Y Berland, M Chollet, H Sichez; Montpellier: J Cristol,
B Canaud, M Morena, A Rodriguez; Nancy: M Kessler,
B Mizejewski, B Risse; Paris-Clinique du Landy: P Urena
Torres, M A Bou-Bekr, C Arezki, P Ras el Qdim; Perpignan-
Hopital Saint Jean: C Vela, F Borsato, A Talairach; Pessac-
Clinique Saint Martin: M Normand, V Normand; Reims:
P Rieu, B Gauthier, C Vigneron-Foy, A Wolak; Vannes-
Centre de Dialyse ECHO: V Menoyo, L Alos; Vienne:
A Caillette-Beaudoin, V Berger.
Germany
Ambulante Dialyse/Gemeinschaftspraxis Augsburg:
S Al-Sarraf, I Konnerth, C Urban; Brüderkrankenhaus
Trier: S Weiner, W Boesken, E Jochum, C Kiefer, A
Wagner; Deutsche Klinik für Diagnostik GmbH
Wiesbaden: B Krumme, J Böhler, B Bonow, U Hohenstatt,
T Mettang, A Röckel; Dialyse Reutlingen: J Langanke,
H Lipponer, G Dunschen-Weimar, R Dunst, E Hübel;
Dialyse Rhein-Ahr, Bad Neuenahr-Ahrweiler: R Petrik,
R Rengel, M Schmidgen; Dialysepraxis Altötting: H Mayr,
C Garschhammer, S Weirauch; Dialysepraxis Arnstadt:
H Anger, T Gööck, A Mai; Dialysepraxis Leipzig: I Bast,
C Süptitz; Dialysepraxis Meiningen: B Iwig, K Florschütz,
R Haβelbacher, G Sauerbrey, S Delrieux, S Rau;
Dialysepraxis Seehausen: M Poley, R Laux, O Schönfelder;
Dialysezentrum/Gemeinschaftspraxis Heilbronn:
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G Kunowski, G Fuchs, K Hoffmann, R Schürger;
Dialysezentrum Bad Godesberg, Bonn: K Brensing,
Z Güven, C Immenkamp, C Kottmann, H Schmitt;
Dialysezentrum Bad Laasphe: M Schulz, P Arnold,
R Knaup, H Schneider, H Siemsen; Dialysezentrum Bad
Malente: P Pyriki, F Körkemeyer, R Pyriki, A Siebrecht;
Dialysezentrum Bovenden: E Schulz, A Krumwiede,
D Kruse, S Lücke; Dialysezentrum Darmstadt: H Keim,
H Fink, S Fischer, A Klingbeil, K Kuhlmei, N Ortwein-
Horn; Dialysezentrum Dormagen: L Merker, B Bayer,
K Benamar, S Emmert, E Floten, K Holzheuer, M Lummer,
E Ossendorf, M Scholz; Dialysezentrum Halberstadt:
M Oppitz, L Georgiew, C Tripps, M Wendehake;
Dialysezentrum Heiligenstadt: D Lange, V Pingel; Dialy-
sezentrum Jacobistraβe Düsseldorf: M Brause,
W Schanze, E Duygulu; Dialysezentrum Karlstraβe
Düsseldorf: F Dellanna, S Heinemann-Nieberding,
C Stürmer, K Wieczorek, O Zarga; Dialysezentrum
Küllmer, Kirchhain: B Küllmer, S Küllmer, M Akin,
M Gondolf, S Schütterle; Dialysezentrum Pirmasens &
Kusel: GWalker, R Bertsch, M Seul, J Allendorff, R Siehler,
S Stemmler; Dialysezentrum Rüsselsheim: M Baldus,
A Adler, S Härter, W Würmell; Dialysezentrum Saarlouis:
M Möller, C Hame, M Müller, M Schreiber, C Schürfeld;
Dialysezentrum Schöneberg-Tempelhof Berlin: M Milli-
ngton-Herrmann, A Benschneider, J Gaffal, U Sprünken;
Dialysezentrum Wilhelmshaven: M Bohling,
S Wunderlich; Dialysezentrum Würzburg: L Schramm, C
Kollenbrath, K Netzer, T Sieber, J Zimmermann;
Gemeinschaftspraxis am Sophienhof Kiel: M Bellersen,
M Uerkvitz; Gemeinschaftspraxis Kiel: T David-Walek,
B Hauschildt, G Leimenstoll; Gemeinschaftspraxis Lan-
genhagen: G Lonnemann, M Hilfenhaus, C Benedetto,
S Stöckmann; Gemeinschaftspraxis Marktredwitz & Selb:
P Ichtiaris, A Jungmann, K Neumeier, A Stoof;
Gemeinschaftspraxis Nürnberg: K Böhmer, A Kirpal,
A Knogl; Gemeinschaftspraxis SchloβHolte-Stukenbrock:
F Flege, K Franke, P Groth, E Parensen; Internistische
Gemeinschaftspraxis Alzey: M Böckmann, P Przyklenk;
Internistische Gemeinschaftspraxis und Dialyse
Friedrichshafen: L Piazolo, L Thinius-Jaudas, A Versen;
Internistische Praxisklinik Kempten: R Hettich, R Arendt,
K Geiger, H Hoppe; Johannes Gutenberg-Universität
Mainz: A Schwarting, T Beyer, J Faust, A Hazenbiller,
S Tschirner; KfH Nierenzentrum Bamberg: C Grupp,
O Dorsch, M Eigner-Schmidtchen, K Michler, J Roth,
S Schramm, G Waldmüller; KfH Nierenzentrum Bayreuth:
B Riedl, H Vögele-Dirks, J Linz; KfH Nierenzentrum
Coburg: P Biggar, H Hennemann, G Bauer, J Buchholz,
P Fischer; KfH Nierenzentrum Donauwörth: W Bihlmaier,
A Baumann, B Peichl; KfH Nierenzentrum Eberswalde:
S Röser, S Ludewig, M Ricksgers, M Szendzielorz; KfH
Nierenzentrum Frankfurt/Oder: A Baus, K Baust,
P Schaller, G Schnellbacher, S Sörensen; KfH Nierenzen-
trum Fürth: B Büschges-Seraphin, L Hauenstein,
B Hofmann, J Nikolay; KfH Nierenzentrum Köln-Mer-
heim: F Merkel, M Nebel, J Petersen, S Schweb; KfH
Nierenzentrum Kulmbach: H Zeiβler, K Baumhackel,
A Krauβ; KfH Nierenzentrum Marl: R Schäfer, A Pastor,
B Zielinski; KfH Nierenzentrum Trier: H Strauβ, H Theis;
KfH NierenzentrumWeiβenburg: K Burkhardt, M Heckel,
K Hussendörfer; KfH Nierenzentrum Würzburg:
U Bahner, M Brandl, B Hammerl-Kraus, D Herrmann,
H Kramer, H Baudenbacher, C Blaser, G Buschmann,
G Eckert, H Ehrich, K Hofmann, U Hüller; Klinikum der
Johann Wolfgang Goethe Universität Frankfurt: H Geiger,
B Becker, S Hoischen, C Bartel, J Hennig, N Obermüller,
C Schulte; Klinikum der LMU München: M Fischereder,
F Burchardi, H Rupprecht, S Weidner, H Anders,
L Andriaccio, S Lederer, G Ricken, C Straβer; Klinikum
Mannheim der Universität Heidelberg, Mannheim:
A Lammert, W Schmitt, F van der Woude, B Langhäuser;
Martin-Luther-Universität Halle: S Markau, B Osten,
D Thiemicke, O Dorligschaw, M Weickert; Medizinische
Universitätsklinik Würzburg: V Krane, F Breunig, G
Denninger, S Osiek, W Rebstöck, P Schulz, F Swoboda, B
Bauer, K Bergmann, D Cavitt, D De Cicco, C Drechsler, I
Dulau, J Harlos, B Kuchenmeister, A Lebert, V Pscheidl, M
Riegel, T Schmiedeke, K Speerschneider, B Stahl;
Nephrologische Gemeinschaftspraxis Hamm-Heessen: U
Hoffmann, M Nölle, P Jankrift, H Pfleiderer, J Witta, B
Wittler; Nephrologische Gemeinschaftspraxis im Heider-
ing Hannover: J Lüth, H Dumann, U Häbel, A Torp;
Nephrologische Gemeinschaftspraxis Rostock:
D Sehland, M Tieβ, C Etzold, A Friederiszik; Nephrolo-
gische Praxis & Dialysezentrum Elsenfeld: A Morgenroth,
A Dybala, A Suffel; Nephrologische Praxis Berlin-Köpe-
nick: T Leimbach, J Kron, S Sauer; Nephrologische Praxis
Dr Meyer Bad Nauheim: T Meyer, M Meyer; Nephrolo-
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